Antifungal therapy--state of the art at the beginning of the 21st century.
The most relevant information on the present state of the art of antifungal chemotherapy is reviewed in this chapter. For dermatomycoses a variety of topical antifungals are available, and safe and efficacious systemic treatment, especially with the fungicidal drug terbinafine, is possible. The duration of treatment can be drastically reduced. Substantial progress in the armamentarium of drugs for invasive fungal infections has been made, and a new class of antifungals, echinocandins, is now in clinical use. The following drugs in oral and/or intravenous formulations are available: the broad spectrum polyene amphotericin B with its new "clothes"; the sterol biosynthesis inhibitors fluconazole, itraconazole, and voriconazole; the glucan synthase inhibitor caspofungin; and the combination partner flucytosine. New therapy schedules have been studied; combination therapy has found a significant place in the treatment of severely compromised patients, and the field of prevention and empiric therapy is fast moving. Guidelines exist nowadays for the treatment of various fungal diseases and maintenance therapy. New approaches interfering with host defenses or pathogenicity of fungal cells are being investigated, and molecular biologists are looking for new targets studying the genomics of pathogenic fungi.
Polak
Annemarie
A
Spitzenrainweg 45, CH-4147 Aesch, Switzerland.
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D005658:Fungi / Q000187:drug effects / Q000648:ultrastructure; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology
D000935:Antifungal Agents